XOMA Royalty Corporation (NASDAQ:XOMA) Short Interest Up 29.0% in February

XOMA Royalty Corporation (NASDAQ:XOMA) was the recipient of a significant increase in short interest in February. As of February 13th, there was short interest totaling 1,356,199 shares, an increase of 29.0% from the January 29th total of 1,051,282 shares. Currently, 11.8% of the shares of the stock are sold short. Based on an average daily trading volume, of 244,666 shares, the short-interest ratio is currently 5.5 days. Based on an average daily trading volume, of 244,666 shares, the short-interest ratio is currently 5.5 days. Currently, 11.8% of the shares of the stock are sold short.

Insiders Place Their Bets

In other news, CEO Owen Hughes acquired 100,000 shares of the company’s stock in a transaction that occurred on Thursday, December 4th. The stock was purchased at an average cost of $25.05 per share, with a total value of $2,505,000.00. Following the purchase, the chief executive officer directly owned 102,000 shares of the company’s stock, valued at approximately $2,555,100. This trade represents a 5,000.00% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 7.20% of the company’s stock.

Hedge Funds Weigh In On XOMA Royalty

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Opaleye Management Inc. boosted its holdings in XOMA Royalty by 14.7% in the 4th quarter. Opaleye Management Inc. now owns 292,590 shares of the biotechnology company’s stock worth $7,780,000 after acquiring an additional 37,503 shares during the period. Squarepoint Ops LLC purchased a new stake in shares of XOMA Royalty during the fourth quarter valued at approximately $237,000. Panagora Asset Management Inc. lifted its position in shares of XOMA Royalty by 24.2% during the fourth quarter. Panagora Asset Management Inc. now owns 21,229 shares of the biotechnology company’s stock worth $564,000 after purchasing an additional 4,135 shares in the last quarter. Barclays PLC lifted its position in shares of XOMA Royalty by 12.1% during the fourth quarter. Barclays PLC now owns 14,822 shares of the biotechnology company’s stock worth $394,000 after purchasing an additional 1,598 shares in the last quarter. Finally, State Street Corp boosted its stake in shares of XOMA Royalty by 4.7% in the fourth quarter. State Street Corp now owns 174,908 shares of the biotechnology company’s stock valued at $4,651,000 after purchasing an additional 7,873 shares during the period. 95.92% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on XOMA shares. TD Cowen raised shares of XOMA Royalty to a “hold” rating in a research note on Friday, February 13th. Stifel Nicolaus set a $50.00 price target on shares of XOMA Royalty in a research report on Friday, December 12th. HC Wainwright cut their price target on shares of XOMA Royalty from $104.00 to $97.00 and set a “buy” rating on the stock in a research note on Thursday, December 11th. Leerink Partners reiterated an “outperform” rating on shares of XOMA Royalty in a report on Tuesday, February 24th. Finally, Benchmark restated a “buy” rating on shares of XOMA Royalty in a report on Friday, December 12th. Three research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, XOMA Royalty presently has a consensus rating of “Moderate Buy” and an average price target of $61.60.

XOMA Royalty Stock Down 2.6%

Shares of NASDAQ XOMA opened at $25.54 on Wednesday. XOMA Royalty has a 12-month low of $18.35 and a 12-month high of $39.92. The company has a market cap of $316.19 million, a P/E ratio of 34.51 and a beta of 0.86. The company has a current ratio of 3.91, a quick ratio of 3.91 and a debt-to-equity ratio of 1.07. The stock has a fifty day moving average price of $26.03 and a 200 day moving average price of $30.96.

About XOMA Royalty

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.